|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Chronic Obstructive Pulmonary Disease (COPD)
Two major diseases contribute to COPD: emphysema and chronic bronchitis. The chief symptoms are chronic cough, spitting or coughing up mucus (expectoration), breathlessness on exertion, and progressive reduction in the ability to breathe out fully. Cigarette smoking accounts for 82% of COPD deaths.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
COPD (Moderate to Severe) Study - A2208
The purpose of this randomized, double-blind, placebo-controlled 2-period, cross over study is to assess the efficacy and safety of an investigational study drug, a long-acting muscarinic antagonist, administered in patients with moderate to severe chronic obstructive pulmonary disease (COPD). An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 2 Participation Duration: For participation in this study you should expect to go to the doctor's office/clinic or study site 18 times over 11 weeks for study visits. Protocol Number: CNVA237A2208 COPD (Severe) Study - A2304
The purpose of this 52-week, randomized, double-blind, parallel-group active controlled study is to assess the effect of one investigational drug versus another on COPD exacerbations in patients with severe to very severe COPD over a 1- year period. An "investigational drug" is a drug that is being clinically tested and is not approved for sale or use in the United States by the Food and Drug Administration (FDA), for the indication in which it is being studied.
Trial phase: Phase 3 Participation Duration: In total, you will attend 14 visits at the clinic in one year. Each visit should take 2-3 hours. Protocol Number: CQVA149A2304 |